19.03.2024 • NewsSanofiEuroAPIAPI Production

2024 Guidance Suspended: API Production Paused in Brindisi, Italy

EuroAPI today announces that its Italian subsidiary, EuroAPI Italy S.R.L., is suspending the production of all APIs (active pharmaceutical ingredients) in Brindisi.

An internal audit at EuroAPI has uncovered potential misconduct leading to quality control issues. Production is on hold pending further investigation. Health authorities have been notified and a forensic audit is underway. Customers will be updated as more information becomes available.

The Brindisi site, which primarily produces anti-infective APIs, generated sales of 63 million euros in 2023, with 43% related to Sanofi. However, due to full impairment of its non-current assets in the 2023 accounts, the Group’s performance is expected to be impacted. As a result, the 2024 guidance is suspended, with a revised outlook to be provided in Q2 2024. This will coincide with updates on the FOCUS-27 project announced on February 28th, 2024.

Company

Logo:

EuroAPI

15 rue Traversière
75012 Paris
France

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation